Go Pro
NYSEAMERICAN:CCEL

Cryo-Cell International (CCEL) Stock Price, News & Analysis

Cryo-Cell International logo
$3.56 +0.08 (+2.30%)
Closing price 04:00 PM Eastern
Extended Trading
$3.54 -0.02 (-0.70%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cryo-Cell International Stock (NYSEAMERICAN:CCEL)

Advanced

Key Stats

Today's Range
$3.51
$3.73
50-Day Range
$2.90
$4.05
52-Week Range
$2.72
$5.43
Volume
10,868 shs
Average Volume
12,158 shs
Market Capitalization
$28.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Cryo-Cell International, Inc. is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth. Trained medical personnel coordinate with healthcare providers to collect cord blood and cord tissue immediately after delivery. Samples are shipped in temperature-controlled containers to Cryo-Cell’s processing laboratories, where stem cell fractions are isolated, tested for purity and viability, and ultimately cryogenically stored in liquid nitrogen tanks.

Cryo-Cell serves families across the United States and in select international markets through a network of distribution partners. In addition to its core storage offerings, the company provides customized preservation plans, educational materials and dedicated client support to prospective parents. Cryo-Cell also collaborates with research institutions and participates in industry initiatives aimed at expanding the therapeutic applications of cord blood and tissue derivatives.

Guided by an experienced management team with expertise in biotechnology, clinical operations and regulatory affairs, Cryo-Cell International continues to invest in advanced processing technologies and service expansion. The company’s focus on safety, compliance and customer engagement positions it as a leading player in the evolving field of regenerative medicine and stem cell banking.

AI Generated. May Contain Errors.

Cryo-Cell International Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
6th Percentile Overall Score

CCEL MarketRank™: 

Cryo-Cell International scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cryo-Cell International has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cryo-Cell International has received no research coverage in the past 90 days.

  • Read more about Cryo-Cell International's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cryo-Cell International is -12.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cryo-Cell International is -12.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.19% of the float of Cryo-Cell International has been sold short.
  • Short Interest Ratio / Days to Cover

    Cryo-Cell International has a short interest ratio ("days to cover") of 0.65, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cryo-Cell International has recently increased by 45.15%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cryo-Cell International does not currently pay a dividend.

  • Dividend Growth

    Cryo-Cell International does not have a long track record of dividend growth.

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Cryo-Cell International this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cryo-Cell International insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    38.59% of the stock of Cryo-Cell International is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    10.44% of the stock of Cryo-Cell International is held by institutions.

  • Read more about Cryo-Cell International's insider trading history.
Receive CCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cryo-Cell International and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CCEL Stock News Headlines

CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
Wall Street Analysts Are Neutral on Top Healthcare Picks
See More Headlines

CCEL Stock Analysis - Frequently Asked Questions

Cryo-Cell International's stock was trading at $3.44 at the start of the year. Since then, CCEL shares have increased by 6.1% and is now trading at $3.65.

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) posted its quarterly earnings results on Wednesday, July, 15th. The company reported $0.07 earnings per share (EPS) for the quarter. The firm earned $7.78 million during the quarter.

Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cryo-Cell International investors own include Meta Platforms (META), Alimera Sciences (ALIM), Crescent Biopharma (CBIO), NVIDIA (NVDA), Aspen Group (ASPU).

Company Calendar

Last Earnings
7/15/2026
Today
8/04/2026
Fiscal Year End
11/30/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NYSEAMERICAN:CCEL
CIK
862692
Employees
90
Year Founded
1989

Profitability

EPS (Trailing Twelve Months)
($1.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.43 million
Net Margins
-7.92%
Pretax Margin
-8.18%
Return on Equity
N/A
Return on Assets
-4.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.71
Quick Ratio
0.69

Sales & Book Value

Annual Sales
$31.57 million
Price / Sales
0.91
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.31) per share
Price / Book
-1.54

Miscellaneous

Outstanding Shares
8,060,000
Free Float
4,951,000
Market Cap
$28.69 million
Optionable
Not Optionable
Beta
0.48

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NYSEAMERICAN:CCEL) was last updated on 8/4/2026 by MarketBeat.com Staff.
From Our Partners